Alnylam Pharmace. buy Stifel Nicolaus
Summary
This prediction is currently active. With a performance of -5.42%, the BUY prediction for Alnylam Pharmace. by Stifel_Nicolaus is down slightly. This prediction currently runs until 27.06.25. The prediction end date can be changed by Stifel_Nicolaus at any time. Stifel_Nicolaus has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Alnylam Pharmace. | -1.097% | -1.097% |
iShares Core DAX® | 1.280% | 1.320% |
iShares Nasdaq 100 | -2.457% | -5.192% |
iShares Nikkei 225® | -2.006% | -1.389% |
iShares S&P 500 | -0.662% | -1.884% |
Comments by Stifel_Nicolaus for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Stifel_Nicolaus for Alnylam Pharmace.
Alnylam Pharmace.
14.09.23
14.09.24
26.07.24